首页 > 最新文献

Therapeutics and Clinical Risk Management最新文献

英文 中文
Application of a Personalized Nursing Pathway for Infection Prevention in Hospitalized Leukemia Patients: A Single-Center Retrospective Cohort Study. 个性化护理路径在白血病住院患者感染预防中的应用:一项单中心回顾性队列研究
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-04 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S550531
Jiang Lin, Qinming Guo, Peimin Zhuang, Xueru Xie, Rongrong Zheng, Xiuli Chen

Objective: To evaluate the effectiveness of a personalized nursing pathway in reducing hospital-acquired infections among leukemia patients during hospitalization through a single-center retrospective analysis.

Methods: This study retrospectively reviewed the clinical records of 291 adult leukemia patients admitted to the Hematology Department of The First Hospital of Putian between January 2018 and December 2022. Patients were divided into two groups based on nursing intervention models: the control group (n = 138) received standard nursing care, while the intervention group (n = 153) was managed using a personalized nursing pathway, which included individualized infection risk assessment, dynamic nursing goals, targeted hygiene protocols, and real-time multidisciplinary coordination. Primary outcomes included infection incidence, infection-related readmission, antibiotic use duration, and length of hospital stay. Secondary outcomes included patient satisfaction and nursing compliance rates.

Results: The incidence of hospital-acquired infections was significantly lower in the intervention group compared to the control group (12.4% vs 24.6%, p < 0.01). The average duration of antibiotic therapy was reduced by 2.6 days (p = 0.015), and hospital stay was shortened by 3.2 days on average (p = 0.022). Patient satisfaction with nursing care improved notably (92.8% vs 78.3%, p < 0.01), and nursing compliance to infection control protocols increased to 95.6% in the intervention group.

Conclusion: A personalized nursing pathway significantly reduces the risk of infection among hospitalized leukemia patients and enhances the efficiency and quality of nursing care. This model offers a feasible, effective approach for infection prevention in high-risk hematology wards and warrants further prospective validation.

目的:通过单中心回顾性分析,评价个性化护理路径对降低白血病患者住院期间医院获得性感染的效果。方法:回顾性分析2018年1月至2022年12月莆田市第一医院血液科收治的291例成人白血病患者的临床资料。根据护理干预模式将患者分为两组:对照组(n = 138)接受标准护理,干预组(n = 153)采用个性化护理路径,包括个性化感染风险评估、动态护理目标、针对性卫生方案和实时多学科协调。主要结局包括感染发生率、感染相关再入院、抗生素使用时间和住院时间。次要结局包括患者满意度和护理依从率。结果:干预组医院获得性感染发生率明显低于对照组(12.4% vs 24.6%, p < 0.01)。平均抗生素治疗时间缩短2.6天(p = 0.015),平均住院时间缩短3.2天(p = 0.022)。干预组患者护理满意度显著提高(92.8% vs 78.3%, p < 0.01),感染控制方案护理依从性提高至95.6%。结论:个性化护理路径可显著降低白血病住院患者感染风险,提高护理效率和质量。该模型为高危血液科病房感染预防提供了可行、有效的方法,值得进一步的前瞻性验证。
{"title":"Application of a Personalized Nursing Pathway for Infection Prevention in Hospitalized Leukemia Patients: A Single-Center Retrospective Cohort Study.","authors":"Jiang Lin, Qinming Guo, Peimin Zhuang, Xueru Xie, Rongrong Zheng, Xiuli Chen","doi":"10.2147/TCRM.S550531","DOIUrl":"10.2147/TCRM.S550531","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness of a personalized nursing pathway in reducing hospital-acquired infections among leukemia patients during hospitalization through a single-center retrospective analysis.</p><p><strong>Methods: </strong>This study retrospectively reviewed the clinical records of 291 adult leukemia patients admitted to the Hematology Department of The First Hospital of Putian between January 2018 and December 2022. Patients were divided into two groups based on nursing intervention models: the control group (n = 138) received standard nursing care, while the intervention group (n = 153) was managed using a personalized nursing pathway, which included individualized infection risk assessment, dynamic nursing goals, targeted hygiene protocols, and real-time multidisciplinary coordination. Primary outcomes included infection incidence, infection-related readmission, antibiotic use duration, and length of hospital stay. Secondary outcomes included patient satisfaction and nursing compliance rates.</p><p><strong>Results: </strong>The incidence of hospital-acquired infections was significantly lower in the intervention group compared to the control group (12.4% vs 24.6%, p < 0.01). The average duration of antibiotic therapy was reduced by 2.6 days (p = 0.015), and hospital stay was shortened by 3.2 days on average (p = 0.022). Patient satisfaction with nursing care improved notably (92.8% vs 78.3%, p < 0.01), and nursing compliance to infection control protocols increased to 95.6% in the intervention group.</p><p><strong>Conclusion: </strong>A personalized nursing pathway significantly reduces the risk of infection among hospitalized leukemia patients and enhances the efficiency and quality of nursing care. This model offers a feasible, effective approach for infection prevention in high-risk hematology wards and warrants further prospective validation.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1657-1665"},"PeriodicalIF":2.8,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12684244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anatomical Foundations and Clinical Utility of Personalized Free Ilioinguinal Zone Flap for Hand Skin and Soft Tissue Defect Reconstruction. 自体髂腹股沟区皮瓣修复手部皮肤软组织缺损的解剖学基础及临床应用。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-03 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S546752
Hui Zhang, Qiu-Jing Luo, Mao-Chao Ding, Jian-Wu Qi

Objective: This study aims to explore the anatomical foundations and clinical utility of personalized free ilioinguinal zone flaps for reconstructing skin and soft tissue defects in the hand.

Methods: Anatomical evaluations of the superficial circumflex iliac and the superficial epigastric arteries and veins were performed on 10 cadavers within the inguinal region. Forty-two patients received flap transplants from January 2017 to December 2022 to repair hand tissue defects. Flap areas ranged from 4.0 cm × 6.0 cm to 11.0 cm × 23.0 cm, with arterial anastomosis ensuring vascular connection to recipient sites. Donor sites were directly sutured for closure and healing.

Results: The arteries, sourced from the femoral artery, were consistently identified in all cadavers, with a common trunk found in 70% of cases. Of the 42 transplants, 40 successfully survived, showing a high efficacy rate. Complications included two vascular crises; one was successfully managed, and one led to necrosis. Post-operative observations included soft flap texture, mild bloating, sensory recovery from S2 to S3, and minimal scarring at the donor site.

Conclusion: The personalized free ilioinguinal zone flap is highly effective for repairing hand skin and soft tissue defects, offering advantages like direct donor site closure and reliable vascularity. This method shows great promise in enhancing outcomes in reconstructive hand surgery.

目的:探讨个性化游离髂腹股沟带皮瓣修复手部皮肤软组织缺损的解剖学基础及临床应用。方法:对10具尸体进行腹股沟内旋髂浅动脉和腹壁浅动静脉的解剖评价。2017年1月至2022年12月,42例患者接受皮瓣移植修复手部组织缺损。皮瓣面积从4.0 cm × 6.0 cm到11.0 cm × 23.0 cm,动脉吻合确保血管与受体部位的连接。供体部位直接缝合缝合愈合。结果:来自股动脉的动脉在所有尸体中都被一致地识别出来,70%的病例发现有一个共同的躯干。42例移植中,40例成功存活,有效率高。并发症包括两次血管危象;一个成功处理,另一个导致坏死。术后观察包括皮瓣质地柔软,轻度腹胀,感觉从S2恢复到S3,供区瘢痕最小。结论:个体化游离髂腹股沟带皮瓣修复手部皮肤软组织缺损,具有供区直接闭合、血管稳定可靠等优点。这种方法在手部再造术中显示出很大的希望。
{"title":"Anatomical Foundations and Clinical Utility of Personalized Free Ilioinguinal Zone Flap for Hand Skin and Soft Tissue Defect Reconstruction.","authors":"Hui Zhang, Qiu-Jing Luo, Mao-Chao Ding, Jian-Wu Qi","doi":"10.2147/TCRM.S546752","DOIUrl":"10.2147/TCRM.S546752","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to explore the anatomical foundations and clinical utility of personalized free ilioinguinal zone flaps for reconstructing skin and soft tissue defects in the hand.</p><p><strong>Methods: </strong>Anatomical evaluations of the superficial circumflex iliac and the superficial epigastric arteries and veins were performed on 10 cadavers within the inguinal region. Forty-two patients received flap transplants from January 2017 to December 2022 to repair hand tissue defects. Flap areas ranged from 4.0 cm × 6.0 cm to 11.0 cm × 23.0 cm, with arterial anastomosis ensuring vascular connection to recipient sites. Donor sites were directly sutured for closure and healing.</p><p><strong>Results: </strong>The arteries, sourced from the femoral artery, were consistently identified in all cadavers, with a common trunk found in 70% of cases. Of the 42 transplants, 40 successfully survived, showing a high efficacy rate. Complications included two vascular crises; one was successfully managed, and one led to necrosis. Post-operative observations included soft flap texture, mild bloating, sensory recovery from S2 to S3, and minimal scarring at the donor site.</p><p><strong>Conclusion: </strong>The personalized free ilioinguinal zone flap is highly effective for repairing hand skin and soft tissue defects, offering advantages like direct donor site closure and reliable vascularity. This method shows great promise in enhancing outcomes in reconstructive hand surgery.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1645-1656"},"PeriodicalIF":2.8,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12684415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Phase Thrombolysis and Functional Outcome for Acute Ischemic Stroke Treated with Endovascular Thrombectomy After Intravenous Thrombolysis. 静脉溶栓后血管内取栓治疗急性缺血性卒中的早期溶栓和功能结局。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-02 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S554227
Siyu Sun, Kang Yuan, Hui Huang, Mengdi Xie, Shuxian Huo, Kejia Deng, Rui Liu, Xinfeng Liu

Background: The efficacy of intravenous thrombolysis (IVT) in treating acute ischemic stroke (AIS) has shown a rapid decline with time; however, the impact of this trend on IVT prior to endovascular thrombectomy (EVT) remains uncertain.

Methods: This study retrospectively analyzed patients from multicenter trials who received EVT after IVT in the anterior circulation. The endpoints included unfavorable outcomes (defined as a 90-day modified Rankin Scale score of 3-6) and hemorrhagic complications. Patients were stratified into two groups based on onset-to-needle time (ONT), with a 2-hour threshold. ONT was defined as the interval from the first observed stroke symptoms (or the last known well state) to the initiation of IVT. Multivariate logistic regression and propensity score matching (PSM) were used to compare outcomes.

Results: Among the 176 patients following PSM (with a median age of 67.5 years and 60.8% being female), the median ONT was 120 minutes (85 minutes vs 176 minutes in early and late phase group), with 88 patients in each group. Multivariate analysis revealed that late phase IVT (ONT > 2 hours) was significantly associated with unfavorable outcomes (odds ratio [OR] = 2.213; 95% confidence interval [CI] = 1.078-4.646; P = 0.032). No significant differences were observed in mortality and hemorrhagic complications between the groups. Subgroup analysis revealed no significant disparities among the predefined subgroups.

Conclusion: Early phase IVT (ONT ≤ 2 hours) before EVT was linked to reduced unfavorable outcomes for AIS. No significant differences were observed among predefined subgroups.

背景:静脉溶栓(IVT)治疗急性缺血性脑卒中(AIS)的疗效随着时间的推移呈快速下降趋势;然而,这种趋势对血管内取栓(EVT)前IVT的影响仍不确定。方法:本研究回顾性分析了多中心试验中在前循环IVT后接受EVT的患者。终点包括不良结局(定义为90天改良Rankin量表评分为3-6)和出血性并发症。患者根据起针时间(ONT)分为两组,阈值为2小时。ONT定义为从首次观察到卒中症状(或最后已知的良好状态)到开始静脉输液的时间间隔。多变量逻辑回归和倾向评分匹配(PSM)用于比较结果。结果:在176例PSM患者中(中位年龄67.5岁,60.8%为女性),中位ONT为120分钟(85分钟vs早期和晚期组176分钟),每组88例。多因素分析显示,晚期IVT (ONT 2小时)与不良结局显著相关(优势比[OR] = 2.213; 95%可信区间[CI] = 1.078-4.646; P = 0.032)。两组之间的死亡率和出血性并发症无显著差异。亚组分析显示预定义亚组之间没有显著差异。结论:EVT前早期IVT (ONT≤2小时)可减少AIS的不良结局。在预定的亚组之间没有观察到显著差异。
{"title":"Early Phase Thrombolysis and Functional Outcome for Acute Ischemic Stroke Treated with Endovascular Thrombectomy After Intravenous Thrombolysis.","authors":"Siyu Sun, Kang Yuan, Hui Huang, Mengdi Xie, Shuxian Huo, Kejia Deng, Rui Liu, Xinfeng Liu","doi":"10.2147/TCRM.S554227","DOIUrl":"10.2147/TCRM.S554227","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of intravenous thrombolysis (IVT) in treating acute ischemic stroke (AIS) has shown a rapid decline with time; however, the impact of this trend on IVT prior to endovascular thrombectomy (EVT) remains uncertain.</p><p><strong>Methods: </strong>This study retrospectively analyzed patients from multicenter trials who received EVT after IVT in the anterior circulation. The endpoints included unfavorable outcomes (defined as a 90-day modified Rankin Scale score of 3-6) and hemorrhagic complications. Patients were stratified into two groups based on onset-to-needle time (ONT), with a 2-hour threshold. ONT was defined as the interval from the first observed stroke symptoms (or the last known well state) to the initiation of IVT. Multivariate logistic regression and propensity score matching (PSM) were used to compare outcomes.</p><p><strong>Results: </strong>Among the 176 patients following PSM (with a median age of 67.5 years and 60.8% being female), the median ONT was 120 minutes (85 minutes vs 176 minutes in early and late phase group), with 88 patients in each group. Multivariate analysis revealed that late phase IVT (ONT > 2 hours) was significantly associated with unfavorable outcomes (odds ratio [OR] = 2.213; 95% confidence interval [CI] = 1.078-4.646; <i>P</i> = 0.032). No significant differences were observed in mortality and hemorrhagic complications between the groups. Subgroup analysis revealed no significant disparities among the predefined subgroups.</p><p><strong>Conclusion: </strong>Early phase IVT (ONT ≤ 2 hours) before EVT was linked to reduced unfavorable outcomes for AIS. No significant differences were observed among predefined subgroups.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1637-1644"},"PeriodicalIF":2.8,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12681206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Cancer Diagnosis and Prognostic Monitoring Through Cell-Free RNA via Liquid Biopsy. 通过液体活检无细胞RNA进行肺癌诊断和预后监测。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-02 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S542338
Yuanming Pan, Chongbo Jiang, Mengchan Ye, Dongmei Li, Jinghui Wang

Lung cancer remains a leading cause of cancer-related mortality worldwide, largely due to challenges in its early detection and effective management. Despite advances in treatment modalities, the complex nature of lung cancer, characterized by its molecular heterogeneity and resistance mechanisms, underscores the need for innovative approaches. Cell-free RNA (cfRNA) has emerged as a promising biomarker with significant clinical applications in lung cancer diagnosis, monitoring, and precision medicine. We explore key themes including the utility of cfRNA in early detection, differentiation between benign and malignant lung nodules, molecular subtyping, and real-time therapeutic monitoring. Advances in liquid biopsy technologies, particularly non-invasive cfRNA analysis, provide dynamic means of tracking tumor evolution. cfRNA biomarkers such as miRNA, long non-coding RNAs, and circular RNAs offer unique insights into tumor biology, paving the way for personalized treatment strategies. Further, we discuss the application of cutting-edge technologies such as AI-driven analytics, next-generation sequencing, and multi-omics integration, which are enhancing the clinical utility of cfRNA in identifying treatment resistance and improving outcomes in immunotherapy, targeted therapy, and chemotherapy. The review addresses significant challenges facing cfRNA applications, including pre-analytical variability, technical limitations in detection methods, economic constraints, and the lack of standardization in clinical protocols. Through multidisciplinary collaborations and standardized methodologies, significant progress can be made toward integrating cfRNA into routine clinical practice. Emphasis is placed on future research directions, which include validating cfRNA biomarkers across diverse populations, streamlining workflows, and addressing scalability issues for real-world applications. This comprehensive exploration positions cfRNA at the forefront of innovations in lung cancer management, offering a pathway for improved diagnostic accuracy and individualized care.

肺癌仍然是世界范围内癌症相关死亡的主要原因,主要是由于其早期发现和有效管理方面的挑战。尽管治疗方式取得了进步,但肺癌的复杂性,其分子异质性和耐药机制的特点,强调了创新方法的必要性。无细胞RNA (Cell-free RNA, cfRNA)已成为一种有前景的生物标志物,在肺癌诊断、监测和精准医疗方面具有重要的临床应用。我们探讨的关键主题包括cfRNA在早期检测、良性和恶性肺结节的区分、分子分型和实时治疗监测中的应用。液体活检技术的进步,特别是无创cfRNA分析,提供了跟踪肿瘤演变的动态手段。cfRNA生物标志物,如miRNA、长链非编码rna和环状rna,为肿瘤生物学提供了独特的见解,为个性化治疗策略铺平了道路。此外,我们还讨论了人工智能驱动分析、下一代测序和多组学整合等前沿技术的应用,这些技术正在增强cfRNA在识别治疗耐药性和改善免疫治疗、靶向治疗和化疗结果方面的临床应用。本综述探讨了cfRNA应用面临的重大挑战,包括分析前变异性、检测方法的技术限制、经济约束和临床方案缺乏标准化。通过多学科合作和标准化的方法,将cfRNA整合到常规临床实践中可以取得重大进展。重点放在未来的研究方向上,包括在不同人群中验证cfRNA生物标志物,简化工作流程,以及解决现实世界应用的可扩展性问题。这一全面的探索将cfRNA定位在肺癌管理创新的前沿,为提高诊断准确性和个性化护理提供了一条途径。
{"title":"Lung Cancer Diagnosis and Prognostic Monitoring Through Cell-Free RNA via Liquid Biopsy.","authors":"Yuanming Pan, Chongbo Jiang, Mengchan Ye, Dongmei Li, Jinghui Wang","doi":"10.2147/TCRM.S542338","DOIUrl":"10.2147/TCRM.S542338","url":null,"abstract":"<p><p>Lung cancer remains a leading cause of cancer-related mortality worldwide, largely due to challenges in its early detection and effective management. Despite advances in treatment modalities, the complex nature of lung cancer, characterized by its molecular heterogeneity and resistance mechanisms, underscores the need for innovative approaches. Cell-free RNA (cfRNA) has emerged as a promising biomarker with significant clinical applications in lung cancer diagnosis, monitoring, and precision medicine. We explore key themes including the utility of cfRNA in early detection, differentiation between benign and malignant lung nodules, molecular subtyping, and real-time therapeutic monitoring. Advances in liquid biopsy technologies, particularly non-invasive cfRNA analysis, provide dynamic means of tracking tumor evolution. cfRNA biomarkers such as miRNA, long non-coding RNAs, and circular RNAs offer unique insights into tumor biology, paving the way for personalized treatment strategies. Further, we discuss the application of cutting-edge technologies such as AI-driven analytics, next-generation sequencing, and multi-omics integration, which are enhancing the clinical utility of cfRNA in identifying treatment resistance and improving outcomes in immunotherapy, targeted therapy, and chemotherapy. The review addresses significant challenges facing cfRNA applications, including pre-analytical variability, technical limitations in detection methods, economic constraints, and the lack of standardization in clinical protocols. Through multidisciplinary collaborations and standardized methodologies, significant progress can be made toward integrating cfRNA into routine clinical practice. Emphasis is placed on future research directions, which include validating cfRNA biomarkers across diverse populations, streamlining workflows, and addressing scalability issues for real-world applications. This comprehensive exploration positions cfRNA at the forefront of innovations in lung cancer management, offering a pathway for improved diagnostic accuracy and individualized care.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1615-1636"},"PeriodicalIF":2.8,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modified Alberta Stroke Program Early CT Score (ASPECTS) of Contrast Extravasation on Dual-Energy CT Predicts Haemorrhagic Transformation and Poor Outcome After Endovascular Thrombectomy. 改进的Alberta卒中程序双能CT造影剂外渗早期CT评分(方面)预测血管内血栓切除术后出血转化和不良预后。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-01 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S522244
Xinyi Chen, Jie Xu, Sheng Zhang, Shunyuan Guo, Huiyuan Wang, Yafei Shang, Panpan Shen, Jiawei Ye, Yu Geng

Purpose: Haemorrhagic transformation (HT) is an unpredictable complication of acute ischaemic stroke with large vessel occlusion following endovascular thrombectomy (EVT), and imaging parameters that are correlated with haemorrhage are unknown. We developed a modified version of the Alberta Stroke Program Early Computed Tomography Score (ASPECTS) by adding a periventricular region to assess cerebral contrast extravasation (CE) on dual-energy computed tomography (DECT) and assessed its predictive value for HT.

Methods: In total, 101 patients who underwent DECT immediately after EVT were prospectively enrolled. CE was defined as incident hyperdensity on iodine overlay maps. We quantified the CT attenuation in Hounsfield units (HU) and iodine concentration within the CE regions. The modified ASPECTS divided the middle cerebral artery vascular territory into 11 regions and added one region (paraventricular) to the original score. CE was scored as 1 point for each region, and the cumulative score was determined. Follow-up imaging was performed within 7 days postoperatively to confirm the occurrence of HT. A receiver operating characteristic (ROC) curve was constructed to assess the predictive value of various DECT-measured parameters for HT.

Results: Overall, 75/101 (74.3%) patients exhibited CE following EVT, and 47/101 (46.5%) patients exhibited HT. In the ROC curve analysis, the DECT parameter with the maximal area under the curve (AUC) for HT was the modified ASPECTS (AUC=0.87), indicating that patients with a modified ASPECTS >2 were more likely to develop HT (sensitivity: 83.0%, specificity: 83.3%). The maximum iodine concentration (AUC=0.76) and maximum CT attenuation (AUC=0.68) in the hyperdense region were also predictors of postoperative HT.

Conclusion: The modified ASPECTS is a practical and sensitive method for assessing postoperative HT risk in patients following EVT.

目的:出血转化(HT)是血管内血栓切除术(EVT)后急性缺血性卒中大血管闭塞的一种不可预测的并发症,与出血相关的影像学参数尚不清楚。我们开发了一个改进版的阿尔伯塔卒中早期计算机断层扫描评分(ASPECTS),通过增加一个心室周围区域来评估双能计算机断层扫描(DECT)上的脑造影剂外渗(CE),并评估其对HT的预测价值。方法:共纳入101例EVT后立即行DECT的患者。CE定义为碘叠加图上的入射高密度。我们量化了Hounsfield单位(HU)的CT衰减和CE区域内的碘浓度。改进后的ASPECTS将大脑中动脉血管区域划分为11个区域,并在原评分基础上增加1个区域(室旁)。每个区域的CE评分为1分,计算总分。术后7天内随访影像学以确认HT的发生。构建受试者工作特征(ROC)曲线,评估ect测量的各项参数对HT的预测价值。结果:总体而言,75/101(74.3%)患者在EVT后出现CE, 47/101(46.5%)患者出现HT。在ROC曲线分析中,HT的DECT参数曲线下面积(AUC)最大的是改良的ASPECTS (AUC=0.87),表明改良的ASPECTS bbb2患者更容易发生HT(敏感性:83.0%,特异性:83.3%)。高密度区的最大碘浓度(AUC=0.76)和最大CT衰减(AUC=0.68)也是术后HT的预测指标。结论:改进的ASPECTS是评估EVT术后HT风险的一种实用、灵敏的方法。
{"title":"Modified Alberta Stroke Program Early CT Score (ASPECTS) of Contrast Extravasation on Dual-Energy CT Predicts Haemorrhagic Transformation and Poor Outcome After Endovascular Thrombectomy.","authors":"Xinyi Chen, Jie Xu, Sheng Zhang, Shunyuan Guo, Huiyuan Wang, Yafei Shang, Panpan Shen, Jiawei Ye, Yu Geng","doi":"10.2147/TCRM.S522244","DOIUrl":"10.2147/TCRM.S522244","url":null,"abstract":"<p><strong>Purpose: </strong>Haemorrhagic transformation (HT) is an unpredictable complication of acute ischaemic stroke with large vessel occlusion following endovascular thrombectomy (EVT), and imaging parameters that are correlated with haemorrhage are unknown. We developed a modified version of the Alberta Stroke Program Early Computed Tomography Score (ASPECTS) by adding a periventricular region to assess cerebral contrast extravasation (CE) on dual-energy computed tomography (DECT) and assessed its predictive value for HT.</p><p><strong>Methods: </strong>In total, 101 patients who underwent DECT immediately after EVT were prospectively enrolled. CE was defined as incident hyperdensity on iodine overlay maps. We quantified the CT attenuation in Hounsfield units (HU) and iodine concentration within the CE regions. The modified ASPECTS divided the middle cerebral artery vascular territory into 11 regions and added one region (paraventricular) to the original score. CE was scored as 1 point for each region, and the cumulative score was determined. Follow-up imaging was performed within 7 days postoperatively to confirm the occurrence of HT. A receiver operating characteristic (ROC) curve was constructed to assess the predictive value of various DECT-measured parameters for HT.</p><p><strong>Results: </strong>Overall, 75/101 (74.3%) patients exhibited CE following EVT, and 47/101 (46.5%) patients exhibited HT. In the ROC curve analysis, the DECT parameter with the maximal area under the curve (AUC) for HT was the modified ASPECTS (AUC=0.87), indicating that patients with a modified ASPECTS >2 were more likely to develop HT (sensitivity: 83.0%, specificity: 83.3%). The maximum iodine concentration (AUC=0.76) and maximum CT attenuation (AUC=0.68) in the hyperdense region were also predictors of postoperative HT.</p><p><strong>Conclusion: </strong>The modified ASPECTS is a practical and sensitive method for assessing postoperative HT risk in patients following EVT.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1603-1614"},"PeriodicalIF":2.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12680501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CHA2DS2-VASc Score Predicts Prognosis in Patients with Acute Coronary Syndrome without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. CHA2DS2-VASc评分预测急性冠脉综合征无房颤患者经皮冠状动脉介入治疗的预后
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-25 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S551947
Xiao Long, Qiao Jin, Luping Jiang, Ran Chen, Lu Hu

Purpose: To evaluate the prognostic value of the CHA2DS2-VASc score for 12-month major adverse cardiovascular events (MACE) in Chinese patients with acute coronary syndrome (ACS) without atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).

Patients and methods: This retrospective study included 992 consecutive ACS patients without AF who underwent PCI from January 2019 to December 2022. Patients were stratified into low- (0-1), moderate- (2), and high-risk (>2) groups based on the CHA2DS2-VASc score. The primary endpoint was MACE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke. Multivariate Cox regression was used to evaluate the association between risk groups and outcomes.

Results: During the 12-month follow-up, MACE occurred in 12.7%, 21.4%, and 28.8% of the low-, moderate-, and high-risk groups, respectively (P<0.01). After adjusting for confounders, the CHA2DS2-VASc score remained independently associated with MACE (HR=2.27, 95% CI: 1.34-3.86 for moderate risk; HR=3.83, 95% CI: 1.90-7.69 for high risk; both P<0.01).

Conclusion: The CHA2DS2-VASc score independently predicts 12-month MACE in non-AF ACS patients after PCI, with risks 2.27-fold higher in moderate-risk and 3.83-fold higher in high-risk patients compared with low-risk patients. This simple, readily available tool may help identify patients at higher risk for MACE and inform secondary prevention strategies.

目的:评价CHA2DS2-VASc评分对经皮冠状动脉介入治疗(PCI)非房颤急性冠脉综合征(ACS)患者12个月主要不良心血管事件(MACE)的预后价值。患者和方法:这项回顾性研究包括992名连续的ACS患者,这些患者在2019年1月至2022年12月期间接受了PCI治疗。根据CHA2DS2-VASc评分将患者分为低(0-1)、中(2)和高危(> - 2)组。主要终点为MACE,定义为全因死亡率、非致死性心肌梗死和非致死性卒中的综合指标。采用多变量Cox回归评价危险组与预后之间的关系。结果:在12个月的随访中,低、中、高风险组的MACE发生率分别为12.7%、21.4%和28.8% (P2DS2-VASc评分与MACE保持独立相关(中度风险组HR=2.27, 95% CI: 1.34-3.86;高风险组HR=3.83, 95% CI: 1.90-7.69;结论:CHA2DS2-VASc评分独立预测PCI术后非房颤ACS患者12个月MACE,与低危患者相比,中危患者风险高2.27倍,高危患者风险高3.83倍。这种简单、容易获得的工具可以帮助识别MACE高风险患者,并为二级预防策略提供信息。
{"title":"CHA<sub>2</sub>DS<sub>2</sub>-VASc Score Predicts Prognosis in Patients with Acute Coronary Syndrome without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.","authors":"Xiao Long, Qiao Jin, Luping Jiang, Ran Chen, Lu Hu","doi":"10.2147/TCRM.S551947","DOIUrl":"10.2147/TCRM.S551947","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the prognostic value of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score for 12-month major adverse cardiovascular events (MACE) in Chinese patients with acute coronary syndrome (ACS) without atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).</p><p><strong>Patients and methods: </strong>This retrospective study included 992 consecutive ACS patients without AF who underwent PCI from January 2019 to December 2022. Patients were stratified into low- (0-1), moderate- (2), and high-risk (>2) groups based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc score. The primary endpoint was MACE, defined as a composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke. Multivariate Cox regression was used to evaluate the association between risk groups and outcomes.</p><p><strong>Results: </strong>During the 12-month follow-up, MACE occurred in 12.7%, 21.4%, and 28.8% of the low-, moderate-, and high-risk groups, respectively (<i>P</i><0.01). After adjusting for confounders, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score remained independently associated with MACE (HR=2.27, 95% CI: 1.34-3.86 for moderate risk; HR=3.83, 95% CI: 1.90-7.69 for high risk; both <i>P</i><0.01).</p><p><strong>Conclusion: </strong>The CHA<sub>2</sub>DS<sub>2</sub>-VASc score independently predicts 12-month MACE in non-AF ACS patients after PCI, with risks 2.27-fold higher in moderate-risk and 3.83-fold higher in high-risk patients compared with low-risk patients. This simple, readily available tool may help identify patients at higher risk for MACE and inform secondary prevention strategies.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1595-1602"},"PeriodicalIF":2.8,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12664308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methodological Confounding from Neuromuscular Reversal and Unreported PACU Data in Intranasal Dexmedetomidine for Extubation [Letter]. 神经肌肉逆转和未报告的PACU数据在鼻内右美托咪定拔管中的方法学混淆[字母]。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-20 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S578858
Hann-Shyan Hwang, Hui-Wen Hsu, Ming-Hui Hung
{"title":"Methodological Confounding from Neuromuscular Reversal and Unreported PACU Data in Intranasal Dexmedetomidine for Extubation [Letter].","authors":"Hann-Shyan Hwang, Hui-Wen Hsu, Ming-Hui Hung","doi":"10.2147/TCRM.S578858","DOIUrl":"10.2147/TCRM.S578858","url":null,"abstract":"","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1593-1594"},"PeriodicalIF":2.8,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12642780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145606086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review Vancomycin Role in Gram Positive Biofilm-Associated Infections: Challenges and Emerging Solutions. 万古霉素在革兰氏阳性生物膜相关感染中的作用:挑战和新兴解决方案。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-14 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S541780
Ohood S Alharbi, Khulud A Alhazmi, Malaz Gazzaz, Sarah Almuhayya, Faye A Aldehalan, Asim T Sharif, Bayan Redwan, Mohannad A Alzain, Wafaa Alhazmi, Hala Altarawneh, Hassan Ahmad Hasan Alfreahat, Sulaiman Bani Abdel-Rahman, Waiel S Halabi, Rawan Altalhi, Bandar Hasan Saleh, Nabeel Hussain Alhussainy, Abdulaziz Alsaedi, Hatoon A Niyazi, Hanouf A Niyazi, Noha A Juma, Manal A Zubair, Mona Alqarni, Noof Helmi, Karem Ibrahem

Biofilm-associated infections pose a significant challenge in clinical settings due to their increased resistance to antibiotics and evasion of host immune responses. These infections are responsible for a large proportion of chronic and recurrent infections, leading to prolonged hospital stays, increased healthcare costs, and elevated morbidity and mortality rates. Vancomycin, a glycopeptide antibiotic, has long been a cornerstone in the treatment of infections caused by Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA). In addition, vancomycin-resistant Enterococcus (VRE) represents an important group of biofilm-forming pathogens, further complicating treatment strategies. However, its efficacy against biofilms remains a subject of ongoing research and debate. The ability of vancomycin to target biofilm-embedded bacteria is often hindered by multiple resistance mechanisms, including poor antibiotic penetration, metabolic adaptation of biofilm-associated cells, and the presence of persister cells. The aim of this review is to evaluate vancomycin's antibiofilm activity by examining its mechanism of action, pharmacokinetics, effectiveness, limitations, and potential strategies to enhance its therapeutic outcomes. Several novel approaches have been explored to augment vancomycin's antibiofilm activity, including combination therapies, adjuvant strategies, and nanotechnology-based drug delivery systems. Understanding these factors is crucial for optimizing therapeutic strategies and overcoming the persistent challenge of biofilm-related infections. This review synthesizes current evidence and highlights areas requiring further research to enhance vancomycin's efficacy against biofilm-associated infections.

生物膜相关感染由于其对抗生素的耐药性增加和逃避宿主免疫反应,在临床环境中构成了重大挑战。这些感染在慢性和复发性感染中占很大比例,导致住院时间延长,医疗费用增加,发病率和死亡率升高。万古霉素是一种糖肽抗生素,长期以来一直是治疗革兰氏阳性细菌,特别是耐甲氧西林金黄色葡萄球菌(MRSA)引起的感染的基石。此外,万古霉素耐药肠球菌(VRE)是一组重要的生物膜形成病原体,进一步复杂化了治疗策略。然而,它对生物膜的功效仍然是一个正在进行的研究和争论的主题。万古霉素靶向包埋生物膜细菌的能力经常受到多种耐药机制的阻碍,包括抗生素渗透能力差、生物膜相关细胞的代谢适应以及持久性细胞的存在。本综述的目的是通过考察万古霉素的作用机制、药代动力学、有效性、局限性和提高其治疗效果的潜在策略来评价万古霉素的抗生物膜活性。已经探索了几种新的方法来增强万古霉素的抗生物膜活性,包括联合治疗、辅助策略和基于纳米技术的药物输送系统。了解这些因素对于优化治疗策略和克服生物膜相关感染的持续挑战至关重要。这篇综述综合了目前的证据,并强调了需要进一步研究的领域,以提高万古霉素对生物膜相关感染的疗效。
{"title":"A Review Vancomycin Role in Gram Positive Biofilm-Associated Infections: Challenges and Emerging Solutions.","authors":"Ohood S Alharbi, Khulud A Alhazmi, Malaz Gazzaz, Sarah Almuhayya, Faye A Aldehalan, Asim T Sharif, Bayan Redwan, Mohannad A Alzain, Wafaa Alhazmi, Hala Altarawneh, Hassan Ahmad Hasan Alfreahat, Sulaiman Bani Abdel-Rahman, Waiel S Halabi, Rawan Altalhi, Bandar Hasan Saleh, Nabeel Hussain Alhussainy, Abdulaziz Alsaedi, Hatoon A Niyazi, Hanouf A Niyazi, Noha A Juma, Manal A Zubair, Mona Alqarni, Noof Helmi, Karem Ibrahem","doi":"10.2147/TCRM.S541780","DOIUrl":"10.2147/TCRM.S541780","url":null,"abstract":"<p><p>Biofilm-associated infections pose a significant challenge in clinical settings due to their increased resistance to antibiotics and evasion of host immune responses. These infections are responsible for a large proportion of chronic and recurrent infections, leading to prolonged hospital stays, increased healthcare costs, and elevated morbidity and mortality rates. Vancomycin, a glycopeptide antibiotic, has long been a cornerstone in the treatment of infections caused by Gram-positive bacteria, particularly methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). In addition, vancomycin-resistant Enterococcus (VRE) represents an important group of biofilm-forming pathogens, further complicating treatment strategies. However, its efficacy against biofilms remains a subject of ongoing research and debate. The ability of vancomycin to target biofilm-embedded bacteria is often hindered by multiple resistance mechanisms, including poor antibiotic penetration, metabolic adaptation of biofilm-associated cells, and the presence of persister cells. The aim of this review is to evaluate vancomycin's antibiofilm activity by examining its mechanism of action, pharmacokinetics, effectiveness, limitations, and potential strategies to enhance its therapeutic outcomes. Several novel approaches have been explored to augment vancomycin's antibiofilm activity, including combination therapies, adjuvant strategies, and nanotechnology-based drug delivery systems. Understanding these factors is crucial for optimizing therapeutic strategies and overcoming the persistent challenge of biofilm-related infections. This review synthesizes current evidence and highlights areas requiring further research to enhance vancomycin's efficacy against biofilm-associated infections.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1569-1578"},"PeriodicalIF":2.8,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12626027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145557858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supine Positioning in Primary Total Hip Replacement is Associated with a Shorter Hospital Stay Than Lateral Positioning: A Retrospective Propensity-Score Matched Cohort Study. 一期全髋关节置换术中仰卧位比侧卧位住院时间短:一项回顾性倾向评分匹配队列研究
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-13 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S553963
Yung-Fong Tsai, Chih-Yi Hsu, Wei-Ti Hsu, Chiung-Wen Lai, Tsung-Yang Lee, Tsan-Wen Huang, Shao-Chun Wu

Background: There is still no definite answer regarding the most advantageous patient positioning during total hip replacement (THR). We compared whether patient position (lateral vs supine) incur a difference on hospital length of stay (LOS) after primary THR.

Methods: This retrospective cohort study included primary THR patients at a single tertiary center (2017-2022). THR patients prepared in the lateral decubitus position were compared to those in the supine position. Propensity score matching at a 1:4 ratio was applied to minimize selection bias. Matching covariates included age, sex, body weight, comorbidities (hypertension, diabetes), anesthesia time, and intraoperative tranexamic acid use. After matching, 990 patients were analyzed (792 lateral; 198 supine).

Results: In supine group, the median LOS (5 days, IQR: 4-6) was shorter than the lateral group (5 days, IQR: 5-6; p<0.001). More supine patients were discharged before day 5 (45.5% vs 22.7%, p<0.001). Multivariate analysis revealed supine position as the strongest protective factor against long hospitalization (OR: 0.32, 95% CI: 0.23-0.46, p<0.001). Other notable predictors of long LOS included ASA ≥III (OR: 1.74), longer anaesthesia duration (OR: 1.78), and higher IV fluid administration (OR: 1.08). Patient positioning did not notably predict blood transfusion risk (OR: 1.32, p=0.144).

Conclusion: THR patients in supine positioning have a substantial reduction in hospital LOS compared to patients in lateral decubitus positioning, with supine position providing a 68% reduction in risk of long hospitalization. The two groups showed no difference in blood transfusion requirements.

背景:关于全髋关节置换术(THR)中最有利的患者体位仍然没有明确的答案。我们比较了患者体位(侧卧位与仰卧位)是否会导致原发性THR后住院时间(LOS)的差异。方法:本回顾性队列研究纳入了单个三级中心(2017-2022)的原发性THR患者。将侧卧位和仰卧位的THR患者进行比较。采用1:4比例的倾向评分匹配,以尽量减少选择偏差。匹配的协变量包括年龄、性别、体重、合并症(高血压、糖尿病)、麻醉时间和术中氨甲环酸的使用。匹配后,分析990例患者(792例侧卧位,198例仰卧位)。结果:仰卧位组中位LOS (5 d, IQR: 4 ~ 6)短于侧卧位组(5 d, IQR: 5 ~ 6), pppp=0.144。结论:与侧卧位的患者相比,仰卧位的THR患者在医院的LOS显著降低,仰卧位可使长期住院的风险降低68%。两组在输血需求方面没有差异。
{"title":"Supine Positioning in Primary Total Hip Replacement is Associated with a Shorter Hospital Stay Than Lateral Positioning: A Retrospective Propensity-Score Matched Cohort Study.","authors":"Yung-Fong Tsai, Chih-Yi Hsu, Wei-Ti Hsu, Chiung-Wen Lai, Tsung-Yang Lee, Tsan-Wen Huang, Shao-Chun Wu","doi":"10.2147/TCRM.S553963","DOIUrl":"10.2147/TCRM.S553963","url":null,"abstract":"<p><strong>Background: </strong>There is still no definite answer regarding the most advantageous patient positioning during total hip replacement (THR). We compared whether patient position (lateral vs supine) incur a difference on hospital length of stay (LOS) after primary THR.</p><p><strong>Methods: </strong>This retrospective cohort study included primary THR patients at a single tertiary center (2017-2022). THR patients prepared in the lateral decubitus position were compared to those in the supine position. Propensity score matching at a 1:4 ratio was applied to minimize selection bias. Matching covariates included age, sex, body weight, comorbidities (hypertension, diabetes), anesthesia time, and intraoperative tranexamic acid use. After matching, 990 patients were analyzed (792 lateral; 198 supine).</p><p><strong>Results: </strong>In supine group, the median LOS (5 days, IQR: 4-6) was shorter than the lateral group (5 days, IQR: 5-6; <i>p</i><0.001). More supine patients were discharged before day 5 (45.5% vs 22.7%, <i>p</i><0.001). Multivariate analysis revealed supine position as the strongest protective factor against long hospitalization (OR: 0.32, 95% CI: 0.23-0.46, <i>p</i><0.001). Other notable predictors of long LOS included ASA ≥III (OR: 1.74), longer anaesthesia duration (OR: 1.78), and higher IV fluid administration (OR: 1.08). Patient positioning did not notably predict blood transfusion risk (OR: 1.32, <i>p</i>=0.144).</p><p><strong>Conclusion: </strong>THR patients in supine positioning have a substantial reduction in hospital LOS compared to patients in lateral decubitus positioning, with supine position providing a 68% reduction in risk of long hospitalization. The two groups showed no difference in blood transfusion requirements.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1579-1591"},"PeriodicalIF":2.8,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12621593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145550978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Stratified Surgical Approach for Convergence Insufficiency-Type Exotropia Based on Near Deviation Magnitude: A Retrospective Cohort Study of Motor and Sensory Outcomes. 基于近偏差大小的收敛不足型外斜视的分层手术方法:运动和感觉结果的回顾性队列研究。
IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-07 eCollection Date: 2025-01-01 DOI: 10.2147/TCRM.S550542
Feng Dong, Ping Liu, Yanyan Wang

Objective:  To evaluate the efficacy and safety of a stratified surgical strategy for convergence insufficiency-type exotropia (CIX(T)) tailored to the magnitude of near deviation, with a primary outcome of postoperative motor success (orthophoria) and a secondary outcome of stereopsis improvement.

Methods:  This retrospective cohort study included 85 CIX(T) patients (near deviation ≥ distance deviation by 15Δ) treated between July 2015 and June 2022. Patients were stratified into three groups based on near deviation magnitude. Group 1 (n=15, <30Δ) underwent unilateral medial rectus resection; Group 2 (n=38, 30-80Δ) received unilateral lateral rectus recession combined with medial rectus resection; Group 3 (n=32, 85-130Δ) underwent bilateral lateral rectus recession plus unilateral medial rectus resection. Ocular alignment (prism cover test) and stereopsis (Titmus test) were assessed preoperatively, at 1 week (short-term), and 3 months (intermediate-term) postoperatively.

Results:  Baseline characteristics were comparable across groups, except for the stratification variable of near deviation. At the 3-month follow-up, motor success was achieved in 20.0% of Group 1, 89.5% of Group 2, and 87.5% of Group 3. Group 1 showed a high rate of undercorrection (80.0%), whereas Groups 2 and 3 demonstrated stable alignment with minimal undercorrection (10.5% and 9.4%, respectively). Stereopsis scores significantly improved from preoperative levels in Group 2 (P<0.001) and Group 3 (P<0.001), but regressed in Group 1 (P>0.05). A planned slight initial overcorrection (10-15Δ) at distance was significantly correlated with better intermediate-term alignment (r = 0.68, 95% CI: 0.51 to 0.80, P<0.001).

Conclusion:  These findings support a stratified surgical approach for CIX(T) based on near deviation magnitude. While combined recession-resection procedures are effective for moderate-to-large angle deviations, unilateral medial rectus resection for small-angle CIX(T) resulted in high rates of undercorrection. This suggests that the surgical plan for small-angle CIX(T) may require more aggressive dosages or alternative strategies.

目的:评估一种分层手术策略治疗收敛不足型外斜视(CIX(T))的有效性和安全性,该策略根据近偏差的大小定制,主要结果是术后运动成功(正斜视),次要结果是立体视改善。方法:本回顾性队列研究纳入2015年7月至2022年6月期间接受治疗的85例CIX(T)患者(近偏差≥距离偏差15Δ)。根据接近偏差大小将患者分为三组。第一组(n=15)结果:各组间基线特征具有可比性,除了接近偏差的分层变量。随访3个月,第1组运动成功率为20.0%,第2组为89.5%,第3组为87.5%。组1显示出高的欠校正率(80.0%),而组2和组3显示出稳定的对齐,最小的欠校正(分别为10.5%和9.4%)。体视评分较术前显著提高(P0.05)。计划在远处进行轻微的初始过度矫正(10-15Δ)与更好的中期对齐显著相关(r = 0.68, 95% CI: 0.51至0.80)。结论:这些发现支持基于近偏差大小的分层手术入路治疗CIX(T)。虽然联合内退-切除手术对中至大角度偏差有效,但单侧内侧直肌切除术治疗小角度CIX(T)会导致高矫正率。这表明小角度CIX(T)的手术计划可能需要更大的剂量或其他策略。
{"title":"A Stratified Surgical Approach for Convergence Insufficiency-Type Exotropia Based on Near Deviation Magnitude: A Retrospective Cohort Study of Motor and Sensory Outcomes.","authors":"Feng Dong, Ping Liu, Yanyan Wang","doi":"10.2147/TCRM.S550542","DOIUrl":"10.2147/TCRM.S550542","url":null,"abstract":"<p><strong>Objective: </strong> To evaluate the efficacy and safety of a stratified surgical strategy for convergence insufficiency-type exotropia (CIX(T)) tailored to the magnitude of near deviation, with a primary outcome of postoperative motor success (orthophoria) and a secondary outcome of stereopsis improvement.</p><p><strong>Methods: </strong> This retrospective cohort study included 85 CIX(T) patients (near deviation ≥ distance deviation by 15Δ) treated between July 2015 and June 2022. Patients were stratified into three groups based on near deviation magnitude. Group 1 (n=15, <30Δ) underwent unilateral medial rectus resection; Group 2 (n=38, 30-80Δ) received unilateral lateral rectus recession combined with medial rectus resection; Group 3 (n=32, 85-130Δ) underwent bilateral lateral rectus recession plus unilateral medial rectus resection. Ocular alignment (prism cover test) and stereopsis (Titmus test) were assessed preoperatively, at 1 week (short-term), and 3 months (intermediate-term) postoperatively.</p><p><strong>Results: </strong> Baseline characteristics were comparable across groups, except for the stratification variable of near deviation. At the 3-month follow-up, motor success was achieved in 20.0% of Group 1, 89.5% of Group 2, and 87.5% of Group 3. Group 1 showed a high rate of undercorrection (80.0%), whereas Groups 2 and 3 demonstrated stable alignment with minimal undercorrection (10.5% and 9.4%, respectively). Stereopsis scores significantly improved from preoperative levels in Group 2 (P<0.001) and Group 3 (P<0.001), but regressed in Group 1 (P>0.05). A planned slight initial overcorrection (10-15Δ) at distance was significantly correlated with better intermediate-term alignment (r = 0.68, 95% CI: 0.51 to 0.80, P<0.001).</p><p><strong>Conclusion: </strong> These findings support a stratified surgical approach for CIX(T) based on near deviation magnitude. While combined recession-resection procedures are effective for moderate-to-large angle deviations, unilateral medial rectus resection for small-angle CIX(T) resulted in high rates of undercorrection. This suggests that the surgical plan for small-angle CIX(T) may require more aggressive dosages or alternative strategies.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1559-1567"},"PeriodicalIF":2.8,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12604517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145506564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutics and Clinical Risk Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1